AnaptysBio, Inc.

ANAB Healthcare Biotechnology

AnaptysBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $234.6 million, up 157.0% from fiscal 2024. In the quarter to March 2026, revenue fell 7.98%, EPS fell 43.8% and free cash flow fell 141.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

46.61 2.10 −4.31%
Market cap
$1.5B
P/E
0.0×
Fwd P/E
220×
Dividend yield
—
F-score
5/9
Altman Z
0.84
Beneish M
−2.34
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Total current assets
350.25 431.88 406.84 447.21 553.88 396.56 377.73 434.22 252.70 58.21
Total non-current assets
14.15 51.96 45.55 163.18 89.19 19.99 57.46 74.78 76.67 3.97
Total Assets
364.40 483.83 452.39 610.38 643.07 416.55 435.20 509.00 329.36 62.18
Total current liabilities
38.63 45.43 37.44 26.05 16.10 19.82 29.54 21.84 14.09 5.71
Total non-current liabilities
288.56 367.54 326.84 322.23 270.54 — 0.65 0.80 7.69 17.20
Total liabilities
327.19 412.97 364.29 348.28 286.64 19.82 30.19 22.63 21.78 22.91
Common Equity (Total)
37.21 70.87 88.10 262.10 356.43 396.73 405.01 486.37 307.58 (38.25)
Shareholders Equity (Total)
37.21 70.87 88.10 262.10 356.43 396.73 405.01 486.37 307.58 39.27
Total Debt
— — — 322.23 19.45 0.34 0.65 0.63 7.55 13.81

Show all line items

In millions of $ except per-share values · columns are period end dates